Tocilizumab for the Treatment of Behcet's Syndrome

NCT01693653 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped low enrollment

Conditions

Behcet Syndrome

Interventions

DRUG: Tocilizumab

Sponsor

NYU Langone Health

Collaborators

[object Object]